Cargando…
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies
BACKGROUND: Although most malignancies express cancer-testis antigens (CTA), immune responses to these proteins are limited in thoracic oncology patients. This trial was undertaken to examine if a cancer cell lysate vaccine could induce immunity to CTA, and to ascertain if metronomic cyclophosphamid...
Autores principales: | Zhang, Mary, Hong, Julie A., Kunst, Tricia F., Bond, Colleen D., Kenney, Cara M., Warga, Cheryl L., Yeray, Javier, Lee, Min-Jung, Yuno, Akira, Lee, Sunmin, Miettinen, Markku, Ripley, R. Taylor, Hoang, Chuong D., Gnjatic, Sacha, Trepel, Jane B., Schrump, David S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350099/ https://www.ncbi.nlm.nih.gov/pubmed/34430349 http://dx.doi.org/10.21037/tlcr-21-1 |
Ejemplares similares
-
Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy
por: Taylor Ripley, R., et al.
Publicado: (2018) -
Metadherin Is a Prognostic Apoptosis Modulator in Mesothelioma Induced via NF-κB-Mediated Signaling()
por: Zhang, Li, et al.
Publicado: (2019) -
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit
por: Tomita, Yusuke, et al.
Publicado: (2021) -
MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis
por: Singh, Anand, et al.
Publicado: (2021) -
Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy
por: Tsuji, Takemasa, et al.
Publicado: (2012)